Opinion: Ending birthright citizenship could be a public health disaster

Sometime before the end of June, the Supreme Court is expected to deliver its opinion in Trump v. Barbara, the case challenging President Trump’s executive order seeking to end birthright citizenship in the United States. At stake is the long-standing interpretation of the Citizenship Clause of the 14th Amendment, which for more than a century has been understood and affirmed to mean that any child born in the United States, regardless of their parents’ citizenship status, is a U.S. citizen (with a remarkably narrow exception carved out for the children of diplomats).

Ending the guarantee of birthright citizenship would dramatically increase the size of the undocumented population in the U.S. and could invite a future executive to nullify the citizenship of countless American-born children of immigrants. It would also have stark consequences at the intersection of bioethics and public health.

Read the rest…

STAT+: A sweeping new AI to detect heart conditions is coming to OpenEvidence

Doctors using OpenEvidence will soon be able to upload an image of an electrocardiogram to get an algorithmic prediction of whether a patient has structural heart disease. 

Called EchoNext, the artificial intelligence model was developed by researchers at New York-Presbyterian Hospital and Columbia University and is being commercialized by a spinout called Pathway Labs. The company this month received a sweeping Food and Drug Administration clearance for the technology that can sniff out six forms of structural heart disease — including conditions where blood doesn’t flow properly through the organ owing to blocked or leaky valves and where the chambers of the heart don’t pump blood as well as they should — from EKG. 

In addition to marketing it to hospitals, Pathway will take the novel step of licensing the technology to OpenEvidence, a medical evidence search engine that’s used by hundreds of thousands of clinicians.

Continue to STAT+ to read the full story…

STAT+: Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?

WASHINGTON — Millions of Americans with obesity are eagerly awaiting a powerful new drug from Eli Lilly called retatrutide, which has demonstrated bariatric-surgery levels of weight loss. Some aren’t even waiting for approval from the Food and Drug Administration, instead racing to acquire it through sketchy means.

But STAT has learned that Eli Lilly and the FDA have allowed one person to gain access to the drug through the FDA’s “compassionate use” program, a pathway that gives patients with serious and immediately life-threatening medical issues access to experimental treatments. 

This person was a 79-year-old man at the time the request was made in April, according to three sources familiar with the matter. Those sources, who requested anonymity due to fear of reprisals, said it drew the interest of top health officials, suggesting the person receiving this drug was well connected.

Continue to STAT+ to read the full story…

Breast and Cervical Cancer Stigma in Rwanda

Conditions: Breast Cancer; Cervical Cancer

Interventions: Behavioral: Behavioral: RISE Intervention; Behavioral: Behavioral: CHW Educational Intervention

Sponsors: Dana-Farber Cancer Institute; Dana-Farber/Harvard Cancer Center (DF/HCC) Boston, MA; American Association for Cancer Research; Breast Cancer Research Foundation

Not yet recruiting

Long‑Range Gene Networks Uncover 641 New Schizophrenia‑Associated Genes

Schizophrenia’s genetic landscape just expanded dramatically. A new study in Nature Genetics identifies 641 previously unrecognized genes associated with schizophrenia, thanks to a modeling framework that captures how distant genetic variants regulate gene expression through co‑expression networks. The work reframes schizophrenia not as a collection of isolated genetic hits, but as a disorder shaped by long‑range regulatory relationships across the brain. The study is titled, “Co‑expression‑based models improve eQTL predictions for transcriptome‑wide association studies and highlight new schizophrenia‑associated genes.”

The research team, led by Giulio Pergola, PhD, at the Lieber Institute for Brain Development (LIBD), developed two trans‑aware predictive models—INGENE and MODULE—that quantify how variants far from a gene influence its expression through co‑regulated partners. Traditional transcriptome‑wide association studies (TWAS) focus almost exclusively on cis‑expression quantitative trait loci (ciseQTLs), variants within ±1 Mb of a gene. But as the paper noted, “Most transcriptome‑wide association approaches primarily model local (cis) genetic effects, leaving much of gene regulation unexplained.” By contrast, the new models incorporate distal (trans) regulatory effects, capturing regulatory relationships that behave more like social networks than neighborhood blocks.

Using RNA‑seq data from six human post‑mortem brain regions and genetic data from more than 102,000 individuals, the team integrated cis‑based predictors (CIS, EpiXcan) with their new trans‑based frameworks. The combined approach improved gene‑expression prediction for 18,744 genes, and when applied to Psychiatric Genomics Consortium (PGC3) datasets, it identified 766 schizophrenia‑associated genes, including 641 not previously detected by TWAS.

Pergola said the field has been “looking for the light under the lamppost, focusing only on genes close to disease‑associated DNA variants.” By illuminating long‑range interactions, he explained, “we’ve essentially turned on lights across the entire neighborhood, revealing how distant genetic variants coordinate to build the genetic basis of schizophrenia.”

The findings converge on pathways involved in glutamate signaling, neuronal communication, immune processes, and neurodevelopment—biological systems repeatedly implicated in psychiatric risk. MODULE‑derived trans‑single nucleotide polymorphisms (SNPs) showed particularly strong enrichment for schizophrenia‑associated variants, and many overlapped with cis‑eQTLs for transcription factors such as GATAD2A, RERE, IRF3, and SP4, all previously prioritized in schizophrenia GWAS.

Daniel Weinberger, MD, CEO and director of LIBD, emphasized the shift in perspective: “Schizophrenia risk isn’t just about individual genes acting one after another—it’s about how networks of genes work together. Understanding these coordinated genetic programs brings us closer to precision psychiatry.”

By demonstrating that trans‑regulatory architecture is both detectable and biologically meaningful, the study provides a roadmap for expanding TWAS beyond local effects. It also underscores the importance of integrating multi‑region brain transcriptomics with large‑scale genetic cohorts to reveal disease‑relevant regulatory relationships.

The post Long‑Range Gene Networks Uncover 641 New Schizophrenia‑Associated Genes appeared first on GEN – Genetic Engineering and Biotechnology News.